Fluid Replacement

for treatment of blood loss

Treatment
Treatment
  • PREVENTION
  • DIAGNOSTIC
  • TREATMENT
  • OVERVIEW
  • TECHNOLOGY Characteristics
  • Fluid Replacement
    Representative Product

    GLOBAL ANNUAL DEATHS ASSOCIATED WITH HEMORRHAGE AND SEVERE ANEMIA

    PERCENT (%)
    NUMBER

    Maternal

    4-45%
    10,000 - 115,000

    Neonatal

    *
    *

    Stillbirth

    *
    *
    *Estimates under development

    Condition
    Fluid replacement helps treat hemorrhage and dehydration in pregnancy. Maternal hemorrhage is the largest single cause of global maternal mortality responsible for 125,000 deaths per year. When the body loses blood, blood pressure falls, the heart has a greater burden, and it is more difficult for the body to oxygenate its tissues. To compensate, the heart rate rises and breathing speeds up. In severe cases, the body will go into shock to divert blood to critical organs only. 


    Mechanism of Action

    Fluid replacement treats dehydration and low blood pressure from bleeding by replacing the volume which was lost.  The increased volume increases blood pressure and improves venous return to the heart. Plasma volume expanders can be crystalloid or colloid. Crystalloids like saline or Lactated Ringer’s are typically less expensive, but only about a quarter of the volume injected stays in the blood stream--the rest goes to the body's extracellular spaces. Colloid substances like Voluven or Hespan are suspensions of larger, insoluble molecules designed to stay in the vessels and keep the fluid there with osmotic pressure. Neither is considered superior in the treatment of obstetric hypovolemia. Volume expanders are typically indicated when blood loss exceeds 15% of total blood volume--typically about 5 liters. Fluid replacement is a first line treatment for the results of obstetric hemorrhage. More severe cases will require restoration of the blood's oxygen transporting capacity through blood transfution or blood substitutes.


    Current use in High-Resource settings
    For volume expansion, crystalloid and colloid solutions are readily available and frequently used with a large caliber intravenous access. These treatments are even available in ambulances or other unusual treatment locations. The use of colloids is sometimes avoided because of their expense, however they are sometimes preferred because of the low volumes required.

    Application in Low-Resource settings
    Crystalloid plasma volume expanders are readily available and used in tertiary care centers and some clinics as a staple product. There are both in country suppliers of saline solutions and some hospitals make their own.

    REPRESENTATIVE DEVICES

    MAKE
    MODEL
    PRICE*
    TECH
    STATUS
    NOTES

    Human Blood

    Whole Blood
    $225
    Whole Blood
    Marketed
    Prices and safety vary

    Hospira

    Voluven
    $70
    Colloid
    Marketed
    Branded, premium product

    Generic

    Lactated Ringer's
    $1
    Crystalloid
    Marketed
    Generic, commodity product

    Oxygen Biotherapeutics

    Oxycyte
    N/A
    Perflourocarbon
    Trials
    Not indicated for hemorrhage

    Perftoran

    Perftoran
    N/A
    Perflourocarbon
    Marketed
    Limited sales beyond Russia

    OPK Biotech

    Hemopure
    N/A
    Bovine Hb
    Discontinued
    Used in South Africa since 2001

    *Per 500mL, Prices are approximated. Actual pricing can, and will vary by marketplace and market conditions.

  • CHARACTERISTICS OF REPRESENTATIVE PRODUCT

    TECHNOLOGY CHARACTERISTICS

    OPERATIONAL PARAMETERS

    POTENTIAL OPPORTUNITIES FOR IMPROVEMENT

    SKILLS

    REQUIRED

    Intended end user
    Training required
    Time required per use
    Physician, NICU nurse
    Hours
    Minutes

    Use of lactated ringer’s still requires considerable skill, not only to set up the IV, but also to prevent overdosing the patient. Too much fluid can result in pulmonary edema.

    ENVIRONMENT/ INFRASTRUCTURE

    Power required
    Waste collection
    Complementary technologies required
    Temperature and storage
    Maintenance
    None
    Sharps
    14-16 gauge needle, tubing, IV stand, sterilizing wipes, tape
    Store at room temperature
    None

    COST

    Device Cost (Approx)
    Cost/course (Approx)
    <$1
    <$1

    Cost of the crystalloid is unlikely to be an issue (relative to other costs of care).

    OTHER

    Portability
    Regulatory
    Efficacy
    500g
    Widely approved
    Clinically equivalent to more expensive colloid solutions

    Additional devices required for impact: Method to diagnose blood loss, method to stop bleeding, measures to estimate shock such as blood pressure, pulse

Sources: Martel, Marie-Jocelyn. Hemorrhagic Shock. SOGC Clinical Practice Guidelines. Society of Obstetricians and Gynecologists of Canada. No. 115 June 2002. Koistinen, Jukka. Building sustainable blood services in developing countries. Transfusion Alternatives in Transfusion Medicine, Volume 10, Number 2, June 2008 , pp. 53-60. Company web sites